靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING CLINICAL TRIAL to EVALUATE the PHARMACOKINETICS, PHARMACODYNAMICS, and SAFETY of NC-001 in PATIENTS with CHRONIC EUVOLEMIC HYPONATREMIA
CHRONIC EUVOLEMIC HYPONATREMIA
100 项与 nephcentric Inc. 相关的临床结果
0 项与 nephcentric Inc. 相关的专利(医药)
100 项与 nephcentric Inc. 相关的药物交易
100 项与 nephcentric Inc. 相关的转化医学